TARS - Tarsus Pharmaceuticals, Inc.
NEXT EARNINGS:
Apr 29, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$89.00
DETAILS
HIGH:
$100.00
LOW:
$68.00
MEDIAN:
$94.00
CONSENSUS:
$89.00
UPSIDE:
18.65%
Market Cap:
3.18B
Volume:
1,884,686
Avg Volume:
584,110
52 Week Range:
38.51-85.25
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.58
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
323
IPO Date:
2020-10-16
EPS (TTM):
-1.59
P/E Ratio:
-51.51
Revenue (TTM):
451.36M
Total Assets:
562.16M
Total Debt:
N/A
Cash & Equiv:
183.64M
Rev Growth (5Y):
47.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $-0.30 | $-0.35 | +14.3% | $118.7M | $144.6M | -17.9% |
| 2025-08-06 | $-0.48 | $-0.33 | -45.5% | $102.7M | $113.0M | -9.2% |
| 2025-05-01 | $-0.64 | $-0.69 | +7.2% | $78.3M | $99.1M | -21.0% |
| 2025-02-25 | $-0.60 | $-0.68 | +11.8% | $66.4M | $64.5M | +3.0% |
| 2024-11-13 | $-0.61 | $-0.94 | +35.1% | $48.1M | $43.2M | +11.4% |
| 2024-08-08 | $-0.88 | $-0.98 | +10.2% | $40.8M | $31.7M | +28.9% |
| 2024-05-08 | $-1.01 | $-1.15 | +12.2% | $27.6M | $17.5M | +58.2% |
| 2024-02-27 | $-1.31 | $-1.37 | +4.4% | $13.1M | $5.7M | +131.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | 0 | 0 | 0 |
| Net Income | (66.42M) | (115.55M) | (135.89M) | (62.09M) | (13.83M) | (26.81M) | (4.67M) | (1.32M) |
| EPS | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M | 171.97M | 58.32M | 2.39M |
| Total Debt | 0 | 72.45M | 30.22M | 20.21M | 1.89M | 831,000 | 164,000 | 0 |
| Cash & Equivalents | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M | 168.13M | 57.95M | 2.35M |
| Operating Cash Flow | (12.45M) | (83.03M) | (117.49M) | (49.03M) | 3.75M | (21.14M) | (3.67M) | (1.18M) |
| Free Cash Flow | (22.31M) | (84.59M) | (123.00M) | (49.54M) | 3.16M | (21.59M) | (3.85M) | (1.19M) |
| FCF per Share | -0.53 | -2.25 | -4.19 | -2.01 | 0.15 | -1.06 | -0.20 | -0.28 |
| Book Value | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M | 165.98M | (6.00M) | (1.35M) |
| Cash & ST Investments | 417.27M | 291.38M | 227.44M | 217.03M | 171.81M | 168.13M | 57.95M | 2.35M |
| ROC Equity | -0.19 | -0.51 | -0.69 | -0.32 | -0.08 | -0.16 | N/A | N/A |